UA75078U - Способ консервативного лечения хронического простатита, осложненного конкрементами в предстательной железе - Google Patents
Способ консервативного лечения хронического простатита, осложненного конкрементами в предстательной железе Download PDFInfo
- Publication number
- UA75078U UA75078U UAU201203850U UAU201203850U UA75078U UA 75078 U UA75078 U UA 75078U UA U201203850 U UAU201203850 U UA U201203850U UA U201203850 U UAU201203850 U UA U201203850U UA 75078 U UA75078 U UA 75078U
- Authority
- UA
- Ukraine
- Prior art keywords
- treatment
- prostate
- patient
- ultrasound
- prostate gland
- Prior art date
Links
- 210000002307 prostate Anatomy 0.000 title claims abstract description 87
- 238000011282 treatment Methods 0.000 title claims abstract description 72
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 29
- 208000013507 chronic prostatitis Diseases 0.000 title claims abstract description 14
- 238000002604 ultrasonography Methods 0.000 claims abstract description 41
- 230000035945 sensitivity Effects 0.000 claims abstract description 13
- 208000034630 Calculi Diseases 0.000 claims abstract description 12
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 6
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 6
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 30
- 230000000387 litholytic effect Effects 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- 230000000844 anti-bacterial effect Effects 0.000 claims description 16
- 239000004575 stone Substances 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 210000003708 urethra Anatomy 0.000 claims description 9
- JQQZCIIDNVIQKO-UHFFFAOYSA-N benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC1=CC=CC=C1 JQQZCIIDNVIQKO-UHFFFAOYSA-N 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 2
- NAVWVHRQSDHCHD-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;potassium Chemical compound [K].OC(=O)CC(O)(C(O)=O)CC(O)=O NAVWVHRQSDHCHD-UHFFFAOYSA-N 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 7
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 description 32
- 210000000265 leukocyte Anatomy 0.000 description 32
- 230000028327 secretion Effects 0.000 description 27
- 244000005706 microflora Species 0.000 description 22
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 20
- 239000000787 lecithin Substances 0.000 description 20
- 229940067606 lecithin Drugs 0.000 description 20
- 235000010445 lecithin Nutrition 0.000 description 20
- 238000001962 electrophoresis Methods 0.000 description 19
- 210000003743 erythrocyte Anatomy 0.000 description 18
- 210000003097 mucus Anatomy 0.000 description 18
- 230000009089 cytolysis Effects 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 16
- 230000036407 pain Effects 0.000 description 16
- 230000003247 decreasing effect Effects 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 208000000509 infertility Diseases 0.000 description 13
- 230000036512 infertility Effects 0.000 description 13
- 201000010653 vesiculitis Diseases 0.000 description 13
- 231100000535 infertility Toxicity 0.000 description 12
- 230000002101 lytic effect Effects 0.000 description 12
- 210000001625 seminal vesicle Anatomy 0.000 description 12
- 210000001015 abdomen Anatomy 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 11
- 230000008025 crystallization Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 101001011637 Dendroaspis polylepis polylepis Toxin MIT1 Proteins 0.000 description 10
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 10
- 239000004327 boric acid Substances 0.000 description 10
- 239000008298 dragée Substances 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 108010022647 Wobenzym Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000000554 physical therapy Methods 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 230000035558 fertility Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 238000010606 normalization Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000000664 rectum Anatomy 0.000 description 5
- 230000001568 sexual effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 5
- 229960001763 zinc sulfate Drugs 0.000 description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 description 5
- 206010018866 Haematospermia Diseases 0.000 description 4
- 208000008982 Hemospermia Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 210000002640 perineum Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010036018 Pollakiuria Diseases 0.000 description 3
- 208000005448 Trichomonas Infections Diseases 0.000 description 3
- 206010044620 Trichomoniasis Diseases 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical class N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000422 nocturnal effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 206010036596 premature ejaculation Diseases 0.000 description 3
- 208000007799 Asthenozoospermia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241000123069 Ocyurus chrysurus Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 206010036774 Proctitis Diseases 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 108010041649 chymopsin Proteins 0.000 description 2
- 239000000571 coke Substances 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000001856 erectile effect Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007915 intraurethral administration Methods 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 108010065073 lidase Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- 230000008756 pathogenetic mechanism Effects 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 108010001898 Phlogenzym Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 206010072020 Pyospermia Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- -1 ectericide Chemical compound 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- BIKXLKXABVUSMH-UHFFFAOYSA-N trizinc;diborate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]B([O-])[O-].[O-]B([O-])[O-] BIKXLKXABVUSMH-UHFFFAOYSA-N 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 150000007971 urates Chemical class 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Способ консервативного лечения хронического простатита, осложненного конкрементами в предстательной железе, включает использование на фоне традиционной терапии (антибактериальной согласно c чувствительностью к антибиотикам, протеолитической, ультразвуковой и лазерной) литолитическим мероприятий курсами, количество которых определяют индивидуально. Как литолитическим меры применяют электрофоретическое введения раствора "калькулиз".
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201203850U UA75078U (ru) | 2012-03-29 | 2012-03-29 | Способ консервативного лечения хронического простатита, осложненного конкрементами в предстательной железе |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201203850U UA75078U (ru) | 2012-03-29 | 2012-03-29 | Способ консервативного лечения хронического простатита, осложненного конкрементами в предстательной железе |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA75078U true UA75078U (ru) | 2012-11-26 |
Family
ID=50843831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201203850U UA75078U (ru) | 2012-03-29 | 2012-03-29 | Способ консервативного лечения хронического простатита, осложненного конкрементами в предстательной железе |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA75078U (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2534853C1 (ru) * | 2013-07-19 | 2014-12-10 | Игорь Владимирович Виноградов | Способ лечения хронического калькулезного простатита |
-
2012
- 2012-03-29 UA UAU201203850U patent/UA75078U/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2534853C1 (ru) * | 2013-07-19 | 2014-12-10 | Игорь Владимирович Виноградов | Способ лечения хронического калькулезного простатита |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2709958C1 (ru) | Способ лечения эректильной дисфункции | |
| UA75078U (ru) | Способ консервативного лечения хронического простатита, осложненного конкрементами в предстательной железе | |
| MARTIN et al. | Disseminated actinomycosis treated with tetracycline | |
| RU2361595C1 (ru) | Способ лечения осложненного урогенитального хламидиоза | |
| RU2509556C2 (ru) | Способ лечения уретрального синдрома у женщин | |
| RU2305575C2 (ru) | Способ лечения больных с экскреторной формой патоспермии | |
| RU2397771C2 (ru) | Способ лечения осложненных форм воспалительных заболеваний придатков матки | |
| RU2321410C1 (ru) | Способ лечения воспалительных процессов | |
| RU2236218C1 (ru) | Способ лечения больных хроническим простатитом | |
| RU2284825C1 (ru) | Способ лечения абсцессов, флегмон мягких тканей | |
| UA75079U (ru) | Литолитическое средство «калькулиз» для консервативного лечения хронического простатита | |
| RU2568369C1 (ru) | Способ лечения аденомы предстательной железы в сочетании с хроническим абактериальным простатитом | |
| RU2445058C1 (ru) | Способ лечения воспалительных заболеваний внутренних женских половых органов | |
| RU2067441C1 (ru) | Способ лечения больных хроническим неспецифическим простатитом | |
| RU2124890C1 (ru) | Способ лечения бактериального вагиноза и воспалительных процессов гениталий | |
| RU2489143C1 (ru) | Способ лечения хронического простатита и эректильной дисфункции | |
| RU2434657C1 (ru) | Способ лечения хронического простатита | |
| RU2260435C2 (ru) | Способ лечения хронических воспалительных процессов внутренних половых органов у женщин | |
| RU2271203C1 (ru) | Способ лечения синдрома хронической тазовой боли, обусловленного заболеваниями предстательной железы или мочевого пузыря | |
| RU2480225C1 (ru) | Способ лечения воспалительных заболеваний половой сферы у женщин | |
| RU2434587C1 (ru) | Способ лечения хронического простатита в сочетании с варикоцеле у детей | |
| RU2145891C1 (ru) | Способ комплексной терапии больных хроническим аднекситом, инфекционно-токсический вариант, неспецифической этиологии | |
| RU2082468C1 (ru) | Способ лечения больных, страдающих краурозом вульвы | |
| RU2564109C1 (ru) | Способ лечения хронического эндоцервицита | |
| JP4656726B2 (ja) | 女性性器の痛みの状態を治療する為のポドフィロトキシンの鎮痛性の使用 |